ClinicalTrials.gg

Program

ABBV-1042

A development code.

In AbbVie's pipeline, M4 Receptor. Its studies are led by AbbVie.

Furthest: phase 1, since Oct 29, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie10 open or runningphase 1since Oct 29, 2025Oct 29, 2025none ahead
  • Named in AbbVie’s own pipeline as ABBV-1042, phase 1, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 29, 2025First study: phase 1 study in Healthy VolunteerFirst studyNCT07222709 · 36 enrolled · United States

TargetBeta

“M4 Receptor”the company's pipeline, read by Claude · source

Other programs on CHRM4

ProgramCompanyFurthest phaseStudies
GlycopyrrolateruleNovartisphase 487
xanomelineruleBristol-Myers Squibbphase 438
emraclidineAbbViephase 218
GXV-813Novartisphase 21
BMS-986521Bristol-Myers Squibbphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07222709Healthy Volunteer · United States1CompletedSep 18, 202636

How it is read

Names in the registry

  • “ABBV-1042”, 1 entry

Codes read as this program: ABBV1042.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.